PDCD1 and gastric cancer: In addition, anti-programmed cell death 1 (PD-1) antibodies, such as nivolumab, sintilimab, and camrelizumab, have been shown to improve overall survival (OS) and progression-free survival (PFS) in locally advanced gastric cancer patients [5–7].